HeartX
VC Fund
Little Rock, United States
HeartX is a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to market.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 83%
Last updated:
For AI agents: llms.txt
Industries HeartX invests in
Health CareMedicalMedical DeviceHealth DiagnosticsSoftware
Stages HeartX invests in
Venture - Series UnknownSeedPre-SeedSeries AFunding Round
Countries HeartX invests in
United StatesUnited KingdomCanadaIsraelSouth Korea
Investment Focus
Industry
- Health Care 12 (100%)
- Medical 7 (58%)
- Medical Device 6 (50%)
- Health Diagnostics 4 (33%)
- Software 3 (25%)
Stage
- Venture - Series Unknown 6 (50%)
- Seed 2 (17%)
- Pre-Seed 2 (17%)
- Series A 1 (8%)
- Funding Round 1 (8%)
Country
- United States 5 (42%)
- United Kingdom 2 (17%)
- Canada 1 (8%)
- Israel 1 (8%)
- South Korea 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Dopl Technologies
|
Dopl Technologies develops remote robotic ultrasound systems that combine robotics, telepresence, and AI to expand access to diagnostic imaging. Its platform enables healthcare providers to perform ultrasound examinations remotely, helping hospitals and clinics address workforce shortages and improve access to imaging services. The company focuseson diagnostic imaging solutions for rural and underserved healthcare settings. | $6.3M / Seed / Jul 27, 2026 | |
Haermonics
|
Haermonics is a provider of flush therapy that integrates solutions for surgical blood loss and wound healing, targeted versatile therapy, and integration within the working environment. | Venture - Series Unknown / Sep 30, 2024 | |
Caristo Diagnostics
|
Caristo Diagnostics is revolutionizing cardiovascular diagnostics and risk prediction with its advanced, AI-based CT imaging analysis tools. | $150K / Venture - Series Unknown / Sep 30, 2024 | |
MultiplAI Health
|
MultiplAI leverages genomics and AI to provide universal remote screening for cardiovascular diseases among other complex diseases. We use a liquid biopsy of whole blood based on RNA sequencing and deep learning looking at all biomarkers in the blood, thus creating a superb biomarker to detect diseases earlier. Our test can be used in continuoustesting both for preventative screening and post-treatment monitoring. Given that it requires only a simple blood sample, it can be administered remotely, anywhere, and costs a fraction of existing diagnostic methods. | Venture - Series Unknown / Sep 30, 2024 | |
Peerbridge Health
|
Peerbridge Health is a mobile health IT company that seeks to bring independence and precision with remote monitoring capabilities for medical, wellness, and performance-based needs including the monitoring of vital signs, with thoughtful design and a seamless user experience. It has two digital health and fitness pioneering patents formedical-grade monitoring of all vital signs, with other patents pending.The company was founded by Angelo Acquista and is based in New York. | Venture - Series Unknown / Sep 30, 2024 | |
Flosonics
|
Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance,emergency department, operating room, and intensive care unit. | $150K / Oct 16, 2023 | |
Mediwhale
|
Medi Whale seeks to achieve sustainable healthcare where every eye can truly be the window to one’s health with our world's first-of-its-kind 1-stop AI screening platform solution for cardiovascular, renal, metabolic risk assessment, and eye disease diagnosis. Our AI Platform was developed through several clinical collaborations (Korea,Singapore, India, UK, and other European datasets) using structured longitudinal event-based datasets for the development of our retinal biomarker engines. RetiCVD® (cardiovascular disease risk assessment): Developed using coronary artery calcium (CAC) score, CAC is recognized as the gold standard for precise CVD risk calculation. Our CVD engine predicts the presence of CAC and provides a stratified probabilistic risk based on US ASCVD and EU SCORE guidelines.RetiCKD® (chronic kidney disease risk assessment): Developed using eGFR and full lab panel, our CKD engine has been demonstrated to achieve better predictive capability as compared to eGFR or full panel analysis.RetiEYE®: Referable Eye Disease engine detects and flags common aging-related eye modalities such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract at its referable disease state.Medi Whale retinal-based systemic biomarkers have been clinically demonstrated to be non-inferior to current gold standards and are recognized by clinical and scientific communities with two Lancet Digital Health publications. | $9M / Series A / Apr 18, 2023 | |
Lumi Health
|
Lumi's "full stack" precision medication manage platform accelerates, improves, and scales clinical decisions on medication selection and dosage. Our platform helps physicians optimize combination medication therapy through a systematic, measurable process, rather than the "trial and error" approach used today. Ourinitial focus is on the 99% of Heart Failure patients who are on incorrect or suboptimal medication therapy. | $150K / Pre-Seed / Oct 18, 2021 | |
Moving Analytics
|
Moving Analytics is a telehealth service provider that specializes in cardiovascular prevention programs. Its first product Movn is an end-to-end, integrated program to deliver remote and virtual cardiac rehab. The platform reduces readmissions and empowers the effective and efficient delivery of quality care to patients based on 30+ years ofresearch in remote disease management from Stanford University. | $150K / Seed / Oct 18, 2021 | |
SoniVie
|
SoniVie is developing an advanced denervation solution to treat pulmonary hypertension. | $150K / Venture - Series Unknown / Oct 18, 2021 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
Medical VC Funds
16,214 investors
FAQ
What does HeartX invest in?
HeartX invests primarily in Health Care, Medical and Medical Device startups, most often at Venture - Series Unknown and Seed stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did HeartX last invest?
The most recent investment recorded for HeartX closed in Jul 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
